Cargando…

Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer

BACKGROUND: The 4th update of the guidelines of the German Medical Association on the diagnosis of irreversible loss of brain function (brain death, BD) has introduced important new regulations regarding the required qualification of the examiners, approved procedures for ancillary testing, and a cl...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoffmann, Olaf, Salih, Farid, Masuhr, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684634/
https://www.ncbi.nlm.nih.gov/pubmed/37462719
http://dx.doi.org/10.1007/s00115-023-01520-5
_version_ 1785151446696591360
author Hoffmann, Olaf
Salih, Farid
Masuhr, Florian
author_facet Hoffmann, Olaf
Salih, Farid
Masuhr, Florian
author_sort Hoffmann, Olaf
collection PubMed
description BACKGROUND: The 4th update of the guidelines of the German Medical Association on the diagnosis of irreversible loss of brain function (brain death, BD) has introduced important new regulations regarding the required qualification of the examiners, approved procedures for ancillary testing, and a clarification regarding the sequencing of diagnostic steps. OBJECTIVE: Investigation of the implementation and practical effects on the diagnosis of brain death. METHOD: Descriptive evaluation of the routine documentation of the German Organ Procurement Organization, comparing the periods July 2011–June 2015 (3rd update) and July 2015–June 2019 (4th update). RESULTS: Patient numbers decreased from 6100 to 5403. The largest decrease affected hospitals without neurosurgery. Children were not affected. With the 4th update, clinical diagnostics were increasingly performed during on-call hours by external neurologists. Of the patients 83.8% now received ancillary tests compared to 80.1% previously. Computed tomography angiography (CTA), first introduced in the 4th update, was applied in 23.2% and established complete loss of cerebral circulation in 89.4%. The time between first documentation of the clinical signs of BD and certification of BD increased from 7.0 ± 12.7 h to 8.2 ± 14.2 h. The diagnosis was slightly less frequent with 95.3% compared to 96.6%. CONCLUSION: The updated standards were implemented in accordance with the guidelines. The demand for external consulting neurologists and neurosurgeons as well as the time required for BD assessment have increased. Negative effects on pediatric BD diagnostics were not apparent. CTA is widely and successfully used in adults as a new ancillary diagnostic procedure.
format Online
Article
Text
id pubmed-10684634
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-106846342023-11-30 Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer Hoffmann, Olaf Salih, Farid Masuhr, Florian Nervenarzt Originalien BACKGROUND: The 4th update of the guidelines of the German Medical Association on the diagnosis of irreversible loss of brain function (brain death, BD) has introduced important new regulations regarding the required qualification of the examiners, approved procedures for ancillary testing, and a clarification regarding the sequencing of diagnostic steps. OBJECTIVE: Investigation of the implementation and practical effects on the diagnosis of brain death. METHOD: Descriptive evaluation of the routine documentation of the German Organ Procurement Organization, comparing the periods July 2011–June 2015 (3rd update) and July 2015–June 2019 (4th update). RESULTS: Patient numbers decreased from 6100 to 5403. The largest decrease affected hospitals without neurosurgery. Children were not affected. With the 4th update, clinical diagnostics were increasingly performed during on-call hours by external neurologists. Of the patients 83.8% now received ancillary tests compared to 80.1% previously. Computed tomography angiography (CTA), first introduced in the 4th update, was applied in 23.2% and established complete loss of cerebral circulation in 89.4%. The time between first documentation of the clinical signs of BD and certification of BD increased from 7.0 ± 12.7 h to 8.2 ± 14.2 h. The diagnosis was slightly less frequent with 95.3% compared to 96.6%. CONCLUSION: The updated standards were implemented in accordance with the guidelines. The demand for external consulting neurologists and neurosurgeons as well as the time required for BD assessment have increased. Negative effects on pediatric BD diagnostics were not apparent. CTA is widely and successfully used in adults as a new ancillary diagnostic procedure. Springer Medizin 2023-07-18 2023 /pmc/articles/PMC10684634/ /pubmed/37462719 http://dx.doi.org/10.1007/s00115-023-01520-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access Dieser Artikel wird unter der Creative Commons Namensnennung 4.0 International Lizenz veröffentlicht, welche die Nutzung, Vervielfältigung, Bearbeitung, Verbreitung und Wiedergabe in jeglichem Medium und Format erlaubt, sofern Sie den/die ursprünglichen Autor(en) und die Quelle ordnungsgemäß nennen, einen Link zur Creative Commons Lizenz beifügen und angeben, ob Änderungen vorgenommen wurden. Die in diesem Artikel enthaltenen Bilder und sonstiges Drittmaterial unterliegen ebenfalls der genannten Creative Commons Lizenz, sofern sich aus der Abbildungslegende nichts anderes ergibt. Sofern das betreffende Material nicht unter der genannten Creative Commons Lizenz steht und die betreffende Handlung nicht nach gesetzlichen Vorschriften erlaubt ist, ist für die oben aufgeführten Weiterverwendungen des Materials die Einwilligung des jeweiligen Rechteinhabers einzuholen. Weitere Details zur Lizenz entnehmen Sie bitte der Lizenzinformation auf http://creativecommons.org/licenses/by/4.0/deed.de (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Originalien
Hoffmann, Olaf
Salih, Farid
Masuhr, Florian
Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer
title Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer
title_full Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer
title_fullStr Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer
title_full_unstemmed Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer
title_short Feststellung des irreversiblen Hirnfunktionsausfalls in Deutschland – Umsetzung der Richtlinie der Bundesärztekammer
title_sort feststellung des irreversiblen hirnfunktionsausfalls in deutschland – umsetzung der richtlinie der bundesärztekammer
topic Originalien
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684634/
https://www.ncbi.nlm.nih.gov/pubmed/37462719
http://dx.doi.org/10.1007/s00115-023-01520-5
work_keys_str_mv AT hoffmannolaf feststellungdesirreversiblenhirnfunktionsausfallsindeutschlandumsetzungderrichtliniederbundesarztekammer
AT salihfarid feststellungdesirreversiblenhirnfunktionsausfallsindeutschlandumsetzungderrichtliniederbundesarztekammer
AT masuhrflorian feststellungdesirreversiblenhirnfunktionsausfallsindeutschlandumsetzungderrichtliniederbundesarztekammer